Drugs / KP-100IT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT04475224 | Jul 2020 → Dec 2022 | spinal cord injury | Kringle Pharma, Inc. | Unknown | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT02193334 Comparator | Jun 2014 → Dec 2017 | spinal cord injury | Kringle Pharma, Inc. | Completed | No outcome recorded |
Press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-06-11 | Kringle Pharma, Inc. | U.S. FDA Orphan Drug Designation Granted to Recombinant Human HGF, KP-100IT,for the Treatment of Acute Spinal Cord Injury kringle-pharma.com ↗ |
| 2025-06-11 | Kringle Pharma, Inc. | 脊髄損傷急性期を対象とする組換えヒトHGFタンパク質（KP-100IT）米国における希少疾病用医薬品指定の取得のお知らせ kringle-pharma.com ↗ |
| 2024-02-09 | Kringle Pharma, Inc. | Topline Data from Phase 3 Study of KP-100IT in Acute Spinal Cord Injury kringle-pharma.com ↗ |
| 2023-10-02 | Kringle Pharma, Inc. | Last Patient Out in Phase 3 Study of KP-100IT for the Treatment of Acute Spinal Cord Injury kringle-pharma.com ↗ |
| 2021-12-09 | Kringle Pharma, Inc. | Last Patient Out in Phase 2 Study of KP-100IT for the Treatment of ALS kringle-pharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KP-100IT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02193334 ↗ |
| Route | Intrathecal | “Intrathecal injection of 0.6 mg HGF starting at 72 hours since the injury and repeating weekly 5 times” NCT02193334 ↗ |